1b2a

MIAMI, July 27, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and…

<!-- Name:DistributionId Value:8754146 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False -->…

Legacy studies employing a single treatment course of two infusions seven days apart demonstrated greatest benefit in three early studies Data support further investigation of novel…

– Data from cohorts 1-6 in the proof-of-concept study showed pegozafermin was generally well tolerated and had beneficial therapeutic effect in reducing liver fat and improving markers of…

OXFORD, United Kingdom, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel…

At week 2, FMX114 demonstrated a statistically significant reduction in both absolute and percent change in ADSI score compared to vehiclePhase 2a safety and efficacy results expected in…

63% of patients achieved 2-point or greater improvement in NAS without worsening of fibrosis; clinically meaningful improvements on registration enabling endpoints of NASH resolution (32%)…

GHENT, Belgium, Dec. 08, 2021 (GLOBE NEWSWIRE) -- MRM Health, a clinical-stage biopharmaceutical company developing next-generation live microbiome consortia therapeutics, announced that…

Interim data from 27 patients, who had completed 3 months in the HBV002 study in chronic Hepatitis B (CHB) patients, demonstrated noted changes in surface antigen (HBsAg) levels, especially…

New sub-analysis presented at The Liver Meeting® 2021 shows treatment with BIO89-100 reduced spleen volume by an average of 11.8% in NASH patients Oral presentation was highlighted by the…